Vanguard Personalized Indexing Management LLC Grows Stock Holdings in Haemonetics Co. (NYSE:HAE)

Vanguard Personalized Indexing Management LLC raised its position in shares of Haemonetics Co. (NYSE:HAE) by 42.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,756 shares of the medical instruments supplier’s stock after purchasing an additional 1,112 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Haemonetics were worth $294,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its position in Haemonetics by 14.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 191,253 shares of the medical instruments supplier’s stock valued at $16,354,000 after purchasing an additional 24,394 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Haemonetics in the fourth quarter worth about $2,039,000. Quantbot Technologies LP increased its holdings in shares of Haemonetics by 2,101.6% in the first quarter. Quantbot Technologies LP now owns 14,068 shares of the medical instruments supplier’s stock worth $1,201,000 after buying an additional 13,429 shares during the period. Silvercrest Asset Management Group LLC purchased a new position in shares of Haemonetics in the first quarter worth about $38,706,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Haemonetics by 132.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock worth $42,930,000 after buying an additional 286,897 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

HAE has been the topic of several analyst reports. Barrington Research reiterated an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a report on Monday, September 23rd. Bank of America initiated coverage on Haemonetics in a report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective on the stock. Citigroup decreased their price objective on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a report on Thursday, August 22nd. JMP Securities reissued a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a research note on Tuesday, August 13th. Finally, CL King began coverage on Haemonetics in a research note on Friday, September 13th. They issued a “buy” rating and a $116.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $106.14.

Haemonetics Stock Performance

Shares of HAE opened at $79.80 on Friday. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35. The business’s 50 day moving average price is $78.93 and its 200-day moving average price is $83.90. Haemonetics Co. has a 52 week low of $70.74 and a 52 week high of $97.97. The stock has a market cap of $4.07 billion, a P/E ratio of 34.85, a P/E/G ratio of 1.19 and a beta of 0.30.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The company had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. During the same period in the prior year, the firm earned $1.05 earnings per share. The business’s revenue for the quarter was up 8.0% compared to the same quarter last year. Equities research analysts anticipate that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Anila Lingamneni sold 2,136 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the transaction, the executive vice president now directly owns 21,410 shares in the company, valued at approximately $1,926,900. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Stewart W. Strong sold 4,312 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the transaction, the insider now directly owns 18,196 shares in the company, valued at approximately $1,658,565.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Anila Lingamneni sold 2,136 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now owns 21,410 shares of the company’s stock, valued at $1,926,900. The disclosure for this sale can be found here. 1.80% of the stock is owned by company insiders.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.